• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MassDevice Earnings Roundup

Titan Pharmaceuticals misses estimates in Q2

August 10, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell yesterday after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The San Francisco, Calif.-based company posted a net loss of -$3.5 million on sales of $77,000 for the 3 months ended June 30. In the same period last year, Titan posted profits of $11.9 million […]

Filed Under: Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Titan Pharmaceuticals

BioDelivery Sciences beats Q2 rev estimates, misses on EPS

August 10, 2017 By Sarah Faulkner

BioDelivery Sciences International

Shares in BioDelivery Sciences International (NSDQ:BDSI) fell today after the pharmaceutical company beat sales estimates but missed earnings expectations on Wall Street with its second quarter results. The Raleigh, N.C.-based company posted a net loss of -$14.9 million on sales of $8.7 million for the 3 months ended June 30, paring losses by 9.7% on sales […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Pharmaceuticals, Sublingual films, Wall Street Beat Tagged With: BioDelivery Sciences International

Inovio tops Q2 sales estimate by $4m

August 9, 2017 By Sarah Faulkner

Inovio Pharmaceuticals

Shares in Inovio Pharmaceuticals (NSDQ:INO) rose today after the pharmaceutical company beat expectations on Wall Street with its second quarter results. The Plymouth Meeting, Penn.-based company posted a net loss of -$9.5 million on sales of $20.4 million for the 3 months ended June 30, for bottom-line growth of 49% compared with the same period last […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Oncology, Wall Street Beat, Women's Health Tagged With: Inovio Pharmaceuticals

Ocular’s new CEO to ‘aggressively’ seek partnerships

August 9, 2017 By Sarah Faulkner

Ocular Therapeutix

Since the start of June, Ocular Therapeutix‘s (NSDQ:OCUL) stock price has fallen more than -45%. The company’s founder and chief executive, Amar Swahney, has stepped down, assuming the role of executive chairman, and the FDA has rejected Ocular’s resubmitted new drug application for its hydrogel plug, Dextenza. Amidst regulatory troubles, Ocular tapped former Mundipharma exec Antony Mattessich to […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Ocular Therapeutix

Clearside Biomedical misses EPS estimate in Q2

August 9, 2017 By Sarah Faulkner

Clearside Biomedical

Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the biopharmaceutical company missed earnings expectations on Wall Street with its second quarter results. The Alpharetta, Ga.-based company posted a net loss of -$13.8 million on sales of $130,000 for the 3 months ended June 30, for bottom-line loss of -169% compared with the same period last year. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Clearside Biomedical

Mylan tumbles on Q2 miss, lowered outlook

August 9, 2017 By Sarah Faulkner

Mylan

Mylan (NSDQ:MYL) shares fell more than -6% this morning after it posted second quarter results that missed analysts’ sales and earnings estimates. The generics-maker announced that it would not include any major U.S. product launches in its forecast for the full-year, citing uncertainty in the U.S. regulatory market. Other generic drugmakers, like Teva Pharmaceuticals (NYSE:TEVA), have posted […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Mylan

Novo Nordisk shares rise on solid Q2 results

August 9, 2017 By Sarah Faulkner

Novo Nordisk

Diabetes drugmaker Novo Nordisk (NYSE:NVO) posted Street-beating second quarter results today, lifting its full-year sales forecast despite lingering concerns relating to U.S. drug pricing pressures. Last year, the Danish company saw shares drop more than 40% after it slashed its long-term operating profit forecasts, citing price pressures in the U.S. market. Today, Novo Nordisk raised its […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Novo Nordisk

Luminex tops Q2 estimates

August 8, 2017 By Sarah Faulkner

Shares in Luminex (NSDQ:LMNX) rose today after the company beat expectations on Wall Street with its second quarter results. The Austin, Tx.-based company posted profits of $5.5 million, or 13¢ per share, on sales of $76.5 million for the 3 months ended June 30, for bottom-line growth of -1.9% on sales growth of 19% compared […]

Filed Under: Diagnostics, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: luminex

MannKind posts mixed Q2

August 8, 2017 By Sarah Faulkner

MannKind

Shares in MannKind Corp. (NSDQ:MNKD) fell slightly this morning after the biopharmaceutical company missed earnings expectations but beat sales estimates on Wall Street with its second quarter results. The Valencia, Calif.-based company posted a net loss of -$35.4 million on sales of $2.2 million for the 3 months ended June 30, for bottom-line loss of -18% on […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: mannkind

Mallinckrodt beats Q2 earnings, misses on revenue

August 8, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Shares in Mallinckrodt Pharmaceuticals (NYSE:MNK) fell today after the company beat earnings estimates but missed on revenue with its second quarter results. The U.K.-based company posted profits of $62.8 million, or 72¢ per share, on sales of $824.5 million for the 3 months ended June 30, for bottom-line loss of -68% on sales loss of -5% […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Interim pages omitted …
  • Page 38
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS